Valuation: Grace Therapeutics, Inc.

Market Cap 56.37M 39.8M 34.91M 32.16M 29.72M 3.8B 57.34M 385M 151M 1.87B 150M 146M 6.44B P/E 2027 *
-4.7x
P/E 2028 * -4.47x
Enterprise Value 56.37M 39.8M 34.91M 32.16M 29.72M 3.8B 57.34M 385M 151M 1.87B 150M 146M 6.44B EV / Sales 2027 *
-
EV / Sales 2028 * 7.2x
Free-Float
74.27%
Yield 2027 *
-
Yield 2028 * -
1 day+0.41%
1 week+3.38%
Current month+7.93%
1 month+6.06%
3 months-31.75%
6 months-33.60%
Current year-29.19%
1 week 2.35
Extreme 2.35
2.58
1 month 2.08
Extreme 2.0782
2.58
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
27.36
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 03/04/2023
Director of Finance/CFO 54 04/01/2024
Chief Tech/Sci/R&D Officer 64 07/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 03/04/2023
Director/Board Member 59 09/10/2023
Date Insider Type Main position Quantity % Market Cap.
01-11Option

Director

10,000 0.0646%
01-11Option

Director

10,000 0.0646%
01-11Option

Chairman

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%+3.38%-20.97%-13.18% 39.71M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%-0.66%+75.79%+93.87% 53.58B
-2.24%+3.59%+19.60%+466.72% 25.63B
-1.60%-6.21%-19.69%-14.84% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+195.12%+357.18% 16.46B
+8.74%+3.51%+53.81% - 14.13B
-1.05%+1.16%+25.08%+196.28% 14.35B
Average -0.56%+1.34%+46.78%+130.70% 24.22B
Weighted average by Cap. -1.02%+0.29%+54.66%+138.22%

Financials

2027 *2028 *
Net sales - 7.83M 5.53M 4.85M 4.47M 4.13M 528M 7.97M 53.43M 20.92M 260M 20.78M 20.33M 895M
Net income -12.76M -9.01M -7.9M -7.28M -6.73M -860M -12.98M -87.03M -34.07M -424M -33.85M -33.11M -1.46B -20.46M -14.45M -12.67M -11.68M -10.79M -1.38B -20.82M -140M -54.65M -679M -54.29M -53.11M -2.34B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
10/07/26 US$2.450 +0.41% 123,132
09/07/26 US$2.440 -2.01% 210,016
08/07/26 US$2.490 -0.80% 109,517
07/07/26 US$2.510 -0.79% 165,799
06/07/26 US$2.530 +6.75% 273,822
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.464CAD
Average target price
8.447CAD
Spread / Average Target
+143.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock